Hematologic Malignancy

Plasma Cell Neoplasm

HematologicNon-malignant831 active trials25 approved drugs26 evidence items

NCIt: C4665
MeSH: D054219

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (117)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 117 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Toward a Cure in Multiple Myeloma: Redefining Induction Therapy and the Role of Autologous Stem Cell Transplant.
Advait Joshi, Benjamin R Puliafito, Diana D Cirstea et al. · Cancer J · Oct 1, 2026 · PMID 42809701 · candidate dictionary pubmed
Managing Novel CAR T-Cell Toxicities in Multiple Myeloma.
Kwan-Keat Ang, Jodi Lipof, Anupama Kumar et al. · Cancer J · Oct 1, 2026 · PMID 42809699 · candidate dictionary pubmed
Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experience.
Lidia Joanna Alberto-López, Oscar Emigdio Melchor-Melo, Miguel Ángel Gómez-Cabrera et al. · Hematology · Dec 31, 2026 · PMID 42685232 · candidate dictionary pubmed
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
Gang An, Jie Jin, Zhen Cai et al. · Hematology · Dec 31, 2026 · PMID 42679119 · candidate dictionary pubmed
STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma.
Oliver Kepp, Guido Kroemer · Oncoimmunology · Dec 31, 2026 · PMID 42740603 · candidate dictionary pubmed
miR-877-5P acts as a tumor suppressor in multiple myeloma by targeting MAPK8: a study on prognostic value and functional mechanism.
Zhimin Bai, Qiulian Luo, Shasha Zhao · Hematology · Dec 31, 2026 · PMID 42781717 · candidate dictionary pubmed

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025.

Tiantian Zhang, Shenyu Wang, Xin Li et al. · Hum Vaccin Immunother · Dec 1, 2026 · PMID 42623170 · candidate dictionary pubmed

Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.

Akira Yuasa, Mitsuhiro Nagano, Yoichi Kamei et al. · J Med Econ · Dec 1, 2026 · PMID 42709039 · candidate dictionary pubmed

Patient-derived mesenchymal stromal cells establish an IL-6 axis that marks progression from smouldering to active multiple myeloma.

Phoebe Elizabeth Blair, Tianyuan Chu, Andrew Robinson et al. · Cytokine · Nov 1, 2026 · PMID 42721887 · candidate dictionary pubmed

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

Angélique Bruyer, Nicolas Robert, Jules Varbedian et al. · Transl Oncol · Oct 1, 2026 · PMID 42664786 · candidate dictionary pubmed

Single-cell and bulk transcriptomic profiling of M2-like tumor-associated macrophages reveals a prognostic signature and an inflammation-metabolism crosstalk program in multiple myeloma.

Hui Zhao, Jing Kang, Huiling Ouyang et al. · Transl Oncol · Oct 1, 2026 · PMID 42636658 · candidate dictionary pubmed

Revision and complication rates after total joint arthroplasty in patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

Jacob D Kodra, Austen Schweinert, Abdullah A Memon et al. · Int Orthop · Oct 1, 2026 · PMID 42706455 · candidate dictionary pubmed

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

Martin F Kaiser, Rachel H Phillip, Sarah R Brown et al. · Lancet Oncol · Oct 1, 2026 · PMID 42705255 · candidate dictionary pubmed

Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation.

Santosh Gautam, Laura Morrison, Philippe Thompson-Leduc et al. · J Manag Care Spec Pharm · Oct 1, 2026 · PMID 42726291 · candidate dictionary pubmed

Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association.

Manas Pustake, Stevenson Ongsyping, Jesus Gomez et al. · BMJ Case Rep · Sep 28, 2026 · PMID 42805625 · candidate dictionary pubmed

NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma.

Bo Hu, Jacob T Edwards, Hardik Modi et al. · Blood · Sep 24, 2026 · PMID 42371798 · candidate dictionary pubmed

Evolution of real-world frontline treatment patterns in multiple myeloma.

Alexander Lazzaro, Kaelyn Nannini, Cenk Yildirim et al. · Blood Adv · Sep 22, 2026 · PMID 42480210 · candidate dictionary pubmed

AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.

Nicolas Basty, Martin Kaiser, Charlotte Pawlyn et al. · Blood Adv · Sep 22, 2026 · PMID 42418394 · candidate dictionary pubmed

Exploring the psychological impact and healthcare experiences of patients living with triple class refractory multiple myeloma: an interpretative phenomenological analysis study.

Noreen Ali, Luke Kuttschreuter, Sandra Quinn et al. · BMJ Open · Sep 21, 2026 · PMID 42767746 · candidate dictionary pubmed

Psychometric evaluation of the PROMIS® Medication Adherence Scale among patients prescribed oral anticancer medication for multiple myeloma.

Sarah M Belcher, Paul Scott, Susan M Sereika et al. · J Patient Rep Outcomes · Sep 19, 2026 · PMID 42791413 · candidate dictionary pubmed

SEI1 complex silences p53 to drive myeloma progression.

Rui Chen, Rui Liu, Zhihong Fang et al. · iScience · Sep 18, 2026 · PMID 42698665 · candidate dictionary pubmed

Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999-2024.

Mohammad Eisa Ali, Federico Ferrari, Ali Shan Hafeez et al. · Cancer Causes Control · Sep 18, 2026 · PMID 42754761 · candidate dictionary pubmed

PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma.

Anaïs Schavgoulidze, Jian Cui, Jessica Encinas Mayoral et al. · Blood · Sep 17, 2026 · PMID 42237635 · candidate dictionary pubmed

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial.

Christoph Schaefers, Cyrus Khandanpour, Mathias Hänel et al. · BMC Cancer · Sep 16, 2026 · PMID 42786443 · candidate dictionary pubmed

The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma.

Can Yue, Bei-Hui Huang, Lin Qi et al. · Int J Mol Sci · Sep 16, 2026 · PMID 42794667 · candidate dictionary pubmed